Int. J. Mol. Sci. 2013, 14(11), 21414-21434; doi:10.3390/ijms141121414
Article

MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer

1,* email, 1,2email, 1email, 3email, 4email, 1email, 5email, 6email, 1email and 1,* email
Received: 22 July 2013; in revised form: 1 October 2013 / Accepted: 9 October 2013 / Published: 29 October 2013
(This article belongs to the Special Issue Molecular Research in Urology)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: The treatment of high-risk prostate cancer (HRPCa) is a tremendous challenge for uro-oncologists. The identification of predictive moleculobiological markers allowing risk assessment of lymph node metastasis and systemic progression is essential in establishing effective treatment. In the current study, we investigate the prognostic potential of miR-205 in HRPCa study and validation cohorts, setting defined clinical endpoints for both. We demonstrate miR-205 to be significantly down-regulated in over 70% of the HRPCa samples analysed and that reconstitution of miR-205 causes inhibition of proliferation and invasiveness in prostate cancer (PCa) cell lines. Additionally, miR-205 is increasingly down-regulated in lymph node metastases compared to the primary tumour indicating that miR-205 plays a role in migration of PCa cells from the original location into extraprostatic tissue. Nevertheless, down-regulation of miR-205 in primary PCa was not correlated to the synchronous presence of metastasis and failed to predict the outcome for HRPCa patients. Moreover, we found a tendency for miR-205 up-regulation to correlate with an adverse outcome of PCa patients suggesting a pivotal role of miR-205 in tumourigenesis. Overall, we showed that miR-205 is involved in the development and metastasis of PCa, but failed to work as a useful clinical biomarker in HRPCa. These findings might have implications for the use of miR-205 as a prognostic or therapeutic target in HRPCa.
Keywords: high-risk prostate cancer; microRNA; miR-205; prognosis; biomarker
PDF Full-text Download PDF Full-Text [1282 KB, uploaded 19 June 2014 05:13 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Kalogirou, C.; Spahn, M.; Krebs, M.; Joniau, S.; Lerut, E.; Burger, M.; Scholz, C.-J.; Kneitz, S.; Riedmiller, H.; Kneitz, B. MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer. Int. J. Mol. Sci. 2013, 14, 21414-21434.

AMA Style

Kalogirou C, Spahn M, Krebs M, Joniau S, Lerut E, Burger M, Scholz C-J, Kneitz S, Riedmiller H, Kneitz B. MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer. International Journal of Molecular Sciences. 2013; 14(11):21414-21434.

Chicago/Turabian Style

Kalogirou, Charis; Spahn, Martin; Krebs, Markus; Joniau, Steven; Lerut, Evelyne; Burger, Maximilian; Scholz, Claus-Jürgen; Kneitz, Susanne; Riedmiller, Hubertus; Kneitz, Burkhard. 2013. "MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer." Int. J. Mol. Sci. 14, no. 11: 21414-21434.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert